Related Experiment Video

Updated: Jul 4, 2026

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

Published on: February 21, 2011

Therapy development for ALS: lessons learned and path forward

Veena Lanka1, Merit Cudkowicz

  • 1Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.

Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|June 25, 2008
PubMed

Insights

Translating promising motor neuron disease therapies from preclinical success to human trials requires addressing past failures. Improving clinical trial design and developing better biomarkers are crucial for advancing treatments for amyotrophic lateral sclerosis (ALS).

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Drug Development

Background:

  • Preclinical models show promise for motor neuron disease therapies.
  • Many promising treatments have failed in human clinical studies.
  • Past failures may stem from incorrect therapeutic targets or flawed trial design.

Purpose of the Study:

  • To review treatment development in amyotrophic lateral sclerosis (ALS).
  • To discuss the strengths and limitations of past ALS clinical trials.
  • To identify critical needs for future ALS therapy development.

Main Methods:

  • Review of existing literature on ALS treatment development.
  • Analysis of past clinical trial designs and outcomes.
  • Identification of challenges and unmet needs in ALS research.

Main Results:

  • Several promising therapies failed in human trials, necessitating a re-evaluation of strategies.
  • Past clinical trials for ALS have exhibited significant limitations.
  • A critical need exists for improved biomarkers and markers of biological activity.

Conclusions:

  • Future ALS therapy development must address reasons for past trial failures.
  • Enhanced clinical trial design, including robust Phase I and II studies, is essential.
  • Development of better biomarkers and activity markers is critical for successful Phase III trials.

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Related Concept Videos

Modeling in Therapy01:26

Modeling in Therapy

Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Learning Disabilities01:25

Learning Disabilities

Learning disabilities are cognitive disorders caused by neurological impairments that affect cognitive functions like language and reading, without indicating overall intellectual or developmental challenges. These disabilities differ from global intellectual or developmental disabilities as they are limited to distinct cognitive functions. Common learning disabilities include dysgraphia, dyslexia, and dyscalculia, each of which impacts unique aspects of learning.
Dyslexia
Dyslexia is a...
Autism Spectrum Disorder01:19

Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Nursing Process for Patient and Caregiver Teaching I: Assessment and Diagnosis01:24

Nursing Process for Patient and Caregiver Teaching I: Assessment and Diagnosis

The nursing process provides a clinical decision-making framework for patients and families to establish and implement a personalized care plan. Since part of the nurse's duties is to teach patients, the steps of the nursing process are the most effective way to approach instruction. The nursing process and the teaching-learning process are inextricably linked.
It is critical to determine the patient's learning needs during the assessment. Determination of learning needs compounds data from the...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Introduction to Language of Pathophysiology ll01:17

Introduction to Language of Pathophysiology ll

This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...